Polymeric nanoparticles for oral delivery of drugs and vaccines: A critical evaluation of in vivo studies

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 22, Issue 5, 2005, Pages 419-463

  Galindo Rodríguez, Sergio A ^a,b,c   Allémann, Eric ^b,d   Fessi, Hatem ^c   Doelker, Eric ^b  

^a Universities of Geneva and Lyon   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITÉ LYON 1   (France)

^d Bracco Suisse SA   (Switzerland)

Author keywords

Bioadhesive nanoparticles; Colloidal carriers; DNA vaccines; Nanoparticle uptake; Oral bioavailability; Oral drug delivery; Oral vaccination; Peptide and protein encapsulation

Indexed keywords

ADHESIVE AGENT; CALCITONIN; CHOLERA TOXIN B SUBUNIT; DARODIPINE; DICLOFENAC; DNA VACCINE; INDOMETACIN; INSULIN; MACROGOL; MIGLYOL; NANOCAPSULE; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; OVALBUMIN; PEPTIDE; POLY(HEXYL 2 CYANOACRYLATE); POLY(ISOBUTYL CYANOACRYLATE); POLY(ISOHEXYL CYANOACRYLATE); POLY(N ISOPROPYLACRYLAMIDE); POLY(N VINYLACETAMIDE); POLY(VINYLAMINE); POLYGLACTIN; POLYMER; POLYMETHACRYLIC ACID; PYRAZINAMIDE; RIFAMPICIN; SALCATONIN; TETANUS TOXOID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; ZIDOVUDINE;

AREA UNDER THE CURVE; COLLOID; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; EVALUATION; GASTROINTESTINAL ABSORPTION; IMMUNE RESPONSE; INFECTION PREVENTION; MICROENCAPSULATION; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; VACCINATION;

EID: 29144461657     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v22.i5.10     Document Type: Review

References (166)

1. Kreuter J, Müller U, Munz K. Quantitative and microautoradiographic study on mouse intestinal distribution of polycyanoacrylate nanoparticles. Int J Pharm 1989;55(1):39-45.
2. Dembri A, Montisci MJ, Gantier JC, Chacun H, Ponchel G. Targeting of 3′-azido 3′-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm Res 2001;18(4):467-473.
3. Damge C, Aprahamian M, Balboni G, Hoeltzel A, Andrieu V, Devissaguet JP. Polyalkylcyanoacrylate nanocapsules increase the intestinal absorption of a lipophilic drug. Int J Pharm. 1987;36(2-3):121-125.
4. Hubert B, Atkinson J, Guerret M, Hoffman M, Devissaguet JP, Maincent P. The preparation and acute antihypertensive effects of a nanocapsular form of darodipine, a dihydropyridine calcium entry blocker. Pharm Res. 1991;8(6):734-738.
5. Lowe JP, Temple CS. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J Pharm Pharmacol. 1994;46:547-552.
6. Sharma A, Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of poly(D,L-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents. 2004;24(6):599-604.
7. Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation. 2002;105(2):230-235.
8. Zili Z, Sfar S, Fessi H. Preparation and characterization of poly-ε-caprolactone nanoparticles containing griseofulvin. Int J Pharm. 2005;294(1-2):261-7.
9. O'Hagan DT, Palin KJ, Davis SS. Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. Vaccine. 1989;7(3):213-216.
10. Sakuma S, Suzuki N, Sudo R, Hiwatari Ki, Kishida A, Akashi M. Optimized chemical structure of nanoparticles as carriers for oral delivery of salmon calcitonin. Int J Pharm. 2002;239(1-2):185-195.
11. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods. 1999;18(3):286-295.
12. Galindo-Rodríguez S, Allémann E, Doelker E, Fessi H. Versatility of three techniques for preparing nanoparticles of different sizes and drug loadings. J Drug Deliv Sci Technol. 2005. In press.
13. Hillery AM, Toth I, Shaw AJ, Florence AT. Co-polymerised peptide particles (CPP) I: synthesis, characterisation and in vitro studies on a novel oral nanoparticulate delivery system. J Control Release. 1996;41(3):271-281.
14. Yoo HS, Oh JE, Lee KH, Park TG. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res. 1999;16(7):1114-1118.
15. Hussain N, Florence AT. Invasin-induced oral uptake of nanospheres: utilising bacterial mechanisms of epithelial cell entry. J Control Release. 1996;41(1-2): S3-S4.
16. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5-24.
17. Lin SY, Chen KS, Teng HH, Li MJ. In vitro degradation and dissolution behaviours of microspheres prepared by three low molecular weight polyesters. J Microencapsul. 2000;17(5):577-586.
18. Park TG. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials. 1995;16(15):1123-1130.
19. Dunne M, Corrigan OI, Ramtoola Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials. 2000;21(16):1659-1668.
20. Zweers MLT, Engbers GHM, Grijpma DW, Feijen J. In vitro degradation of nanoparticles prepared from polymers based on D,L-lactide, glycolide and poly(ethylene oxide). J Control Release. 2004;100(3):347-356.
21. Prokop A, Kozlov E, Newman GW, Newman MJ. Water-based nanoparticulate polymeric system for protein delivery: permeability control and vaccine application. Biotechnol Bioeng. 2002;78(4):459-466.
22. Callender DP, Jayaprakash N, Bell A, Petraitis V, Petratienes R, Candelario M, et al. Pharmacokinetics of oral zidovudine entrapped in biodegradable nanospheres in rabbits. Antimicrob Agents Chemother. 1999;43(4):972-974.
23. Dunn JM, Hollister AS. Oral biovailability of heparin using a novel delivery system. Curr Ther Res. 1995;56(8):738-745.
24. Arangoa MA, Campanero MA, Renedo MJ, Ponchel G, Irache JM. Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics. Pharm Res. 2001;18(11):1521-1527.
25. Wang Xq, Dai Jd, Chen Z, Zhang T, Xia Gm, Nagai T, et al. Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. J Control Release. 2004;97(3):421-429.
26. Scherer D, Mooren FC, Kinne RKH, Kreuter J. In vitro permeability of PBCA nanoparticles through porcine small intestine. J Drug Target. 1993;1:21-27.
27. Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KHG. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine. 2001;19(15-16):1940-1950.
28. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999;5(4):387-391.
29. Herrmann JE, Chen SC, Jones DH, Tinsley-Bown A, Fynan EF, Greenberg HB, et al. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology. 1999;259(1):148-153.
30. Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chaturvedl P, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature. 1997;386(6623):410-414.
31. Leroux JC, Cozens R, Roesel JL, Galli B, Kubel F, Doelker E, et al. Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J Pharm Sci. 1995;84(12):1387-1391.
32. Leroux JC, Cozens RM, Roesel JL, Galli B, Doelker E, Gurny R. pH-sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs. Pharm Res. 1996;13(3):485-487.
33. De Jaeghere F, Allémann E, Kubel F, Galli B, Cozens R, Doelker E, et al. Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J Control Release. 2000;68(2):291-298.
34. Dai J, Nagai T, Wang X, Zhang T, Meng M, Zhang Q. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine A. Int J Pharm. 2004;280(1-2):229-240.
35. Bodmeier R, Chen HG, Paeratakul O. A novel approach to the oral delivery of micro- or nanoparticles. Pharm Res. 1989;6(5):413-417.
36. Akiyama Y, Nagahara N, Kashihara T, Hirai S, Toguchi H. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative. Pharm Res. 1995;12(3):397-405.
37. Lamprecht A, Schafer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res. 2001;18(6):788-793.
38. Norris DA, Sinko PJ. Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin. J Appl Polym Sci. 1997;63(11):1481-1492.
39. Szentkuti L. Light microscopical observations on luminally administered dyes, dextrans, nanospheres and microspheres in the pre-epithelial mucus gel layer of the rat distal colon. J Control Release. 1997;46(3):233-242.
40. McClean S, Prosser E, Meehan E, O'Malley D, Clarke N, Ramtoola Z, et al. Binding and uptake of biodegradable poly-D,L-lactide micro- and nanoparticles in intestinal epithelia. Eur J Pharm Sci. 1998;6(2):153-163.
41. Couvreur P. Polyalkylcyanoacrylates as colloidal drug carriers. Crit Rev Ther Drug Carrier Syst. 1988;5(1):1-20.
42. Rowland RN, Woodley JF. The stability of liposomes in vitro to pH, bile salts and pancreatic lipase. BBA Lipids Lipid Met. 1980;620(3):400-409.
43. Chia-Ming C, Weiner N. Gastrointestinal uptake of liposomes. I. In vitro and in situ studies. Int J Pharm. 1987;37(1-2):75-85.
44. Saez A, Guzman M, Molpeceres J, Aberturas MR. Freeze-drying of polycaprolactone and poly(D,L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur J Pharm Biopharm. 2000;50(3):379-387.
45. Ahlin P, Kristl J, Kristl A, Vrecer F. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm. 2002;239(1-2):113-120.
46. De Jaeghere F, Allemann E, Leroux JC, Stevels W, Feijen J, Doelker E, et al. Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharm Res. 1999;16(6):859-866.
47. Schaffazick SR, Pohlmann AR, Dalla-Costa T, Guterres SS. Freeze-drying polymeric colloidal suspensions: nanocapsules, nanospheres and nanodispersion. A comparative study. Eur J Pharm Biopharm. 2003;56(3):501-505.
48. Raffin Pohlmann A, Weiss V, Mertins O, Pesce da Silveira N, Staniscuaski Guterres S. Spray-dried indomethacin-loaded polyester nanocapsules and nanospheres: development, stability evaluation and nanostructure models. Eur J Pharm Sci. 2002;16(4-5):305-312.
49. Schmidt C, Bodmeier R. Incorporation of polymeric nanoparticles into solid dosage forms. J Control Release. 1999;57(2):115-125.
50. Galindo-Rodríguez S, Allémann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res. 2004;21(8):1428-1439.
51. Araujo L, Sheppard M, Lobenberg R, Kreuter J. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution after suspension in surfactant solutions and in oil vehicles. Int J Pharm. 1999;176(2):209-224.
52. Watnasirichaikul S, Rades T, Tucker G, Davies NM. In vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J Pharm Pharmacol. 2002;54(4):473-480.
53. De Jaeghere F, Doelker E, Gurny R. Nanoparticles. In: Mathiowitz E, editor. Encyclopedia of controlled drug delivery. New York: John Wiley, 1999.
54. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1-2):1-20.
55. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst. 2002;19(2):99-134.
56. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci. 2002;6(4):319-327.
57. Montasser I, Briançon S, Lieto J, Fessi H. Méthodes d'obtention et mécanismes de formation de nanoparticules polymériques. J Pharm Belg. 2000;55(6):155-167.
58. De Labouret A, Thioune O, Fessi H, Devissaguet JP, Puisieux F. Application of an original process for obtaining colloidal dispersions of some coating polymers: preparation, characterization, industrial scale-up. Drug Dev Ind Pharm. 1995;21(2):229-241.
59. Colombo AP, Briancon S, Lieto J, Fessi H. Project, design, and use of a pilot plant for nanocapsule production. Drug Dev Ind Pharm. 2001;27(10):1063- 1072.
60. Galan Valdivia FJ, Vallet Mas JA, Bergamini MVW. Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles. US patent 5,705,196. Jan. 1998.
61. Galindo-Rodríguez SA, Puel F, Briancon S, Allémann E, Doelker E, Fessi H. Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles. Eur J Pharm Sci. 2005;25(4-5):357-67.
62. Beck PH, Kreuter J, Muller WEG, Schatton W. Improved peroral delivery of avarol with polybutylcyanoacrylate nanoparticles. Eur J Pharm Biopharm. 1994;40(3):134-137.
63. Sakuma S, Suzuki N, Kikuchi H, Hiwatari Ki, Arikawa K, Kishida A, et al. Absorption enhancement of orally administered salmon calcitonin by polystyrene nanoparticles having poly(N-isopropylacrylamide) branches on their surfaces. Int J Pharm. 1997;158(1):69-78.
64. Couvreur P, Lenaerts V, Kante B, Roland M, Speiser P. Oral and parenteral administration of insulin associated to hydrolysable nanoparticles. Acta Pharm Technol. 1980;26(4):220-222.
65. Ammoury N, Dubrasquet M, Fessi H, Devissaguet JP, Puisieux F, Benita S. Idomethacin-loaded poly(D,L-lactide) nanocapsules: protection from gastrointestinal ulcerations and anti-inflammatory activity evaluation in rats. Clin Mater. 1993;13:121-130.
66. Guterres SS, Fessi H, Barratt G, Puisieux F, Devissaguet JP. Poly(D,L-lactide) nanocapsules containing nonsteroidal anti- inflammatory drugs: gastrointestinal tolerance following intravenous and oral administration. Pharm Res. 1995;12(10):1545-1547.
67. Damge C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP. Nanocapsules as carriers for oral peptide delivery. J Control Release. 1990;13(2-3):233-239.
68. Sakuma S, Ishida Y, Sudo R, Suzuki N, Kikuchi H, Hiwatari K, et al. Stabilization of salmon calcitonin by polystyrene nanoparticles having surface hydrophilic polymeric chains, against enzymatic degradation. Int J Pharm. 1997;159(2):181-189.
69. Tobio M, Sanchez A, Vila A, Soriano I, Evora C, Vila-Jato JL, et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf B. 2000;18(3-4):315-323.
70. Nelson J, Reynolds-Kohler C, Margaretten W, Wiley C, Reese C, Levy J. Human immunodeficiency virus detected in bowel epithelium from patients with gastrointestinal symptoms. Lancet. 1988;1(8580):259-262.
71. Ammoury N, Fessi H, Devissaguet JP, Dubrasquet M, Benita S. Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(D,L-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in rats. Pharm Res. 1991;8(1):101-105.
72. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis. 2003;83(6):373-378.
73. Sai P, Damge C, Rivereau AS, Hoeltzel A, Gouin E. Prophylactic oral administration of metabolically active insulin entrapped in isobutylcyanoacrylate nanocapsules reduces the incidence of diabetes in nonobese diabetic mice. J Autoimmun. 1996;9(6):713-721.
74. Damge C, Vranckx H, Balschmidt P, Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci. 1997;86(12):1403-1409.
75. Scherer D, Robinson JR, Kreuter J. Influence of enzymes on the stability of poly-butylcyanoacrylate nanoparticles. Int J Pharm. 1994;101(1-2):165-168.
76. Sakuma S, Suzuki N, Kikuchi H, Hiwatari Ki, Arikawa K, Kishida A, et al. Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. Int J Pharm. 1997;149(1):93-106.
77. Sakuma S, Hayashi M, Akashi M. Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Deliv Rev. 2001;47(1):21-37.
78. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release. 2002;78(1-3):15-24.
79. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev. 1998;34(2-3):191-219.
80. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev. 2001;47(1):39-54.
81. Ponchel G, Montisci MJ, Dembri A, Durrer C, Duchêne D. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur J Pharm Biopharm. 1997;44(1):25-31.
82. Luessen H, Verhoef JC, de Boer AG, Junginger HE, de Leeuw BJ, Borchard G, et al. Multifunctional polymers for the peroal delivery of peptide drugs. In: Mathiowitz E, Chickering DE, Lehr CM, editors. Bioadhesive drug delivery systems-fundamentals, novel approaches, and development. New York: Marcel Dekker, 1999.
83. Durrer C, Irache JM, Puisieux F, Duchene D, Ponchel G. Mucoadhesion of latexes. II. Adsorption isotherms and desorption studies. Pharm Res. 1994;11(5):680-683.
84. Pimienta C, Chouinard F, Labib A, Lenaerts V. Effect of various poloxamer coatings on in vitro adhesion of isohexylcyanoacrylate nanospheres to rat ileal segments under liquid flow. Int J Pharm. 1992;80(1-3):1-8.
85. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive D,L-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol. 2000;5(1):77-85.
86. Arbos P, Campanero MA, Arangoa MA, Renedo MJ, Irache JM. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Release. 2003;89(1):19-30.
87. Sakuma S, Sudo R, Suzuki N, Kikuchi H, Akashi M, Hayashi M. Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract. Int J Pharm. 1999;177(2):161-172.
88. nd Int Symp Control Release Bioact Mater. 1995;314-315.
89. Chickering D, Jacob J, Mathiowitz E. Poly(fumaric-co-sebacic) microspheres as oral drug delivery systems. Biotechnol Bioeng. 1996;52(1):96-101.
90. Lehr CM, Poelma FGJ, Junginger HE, Tukker JJ. An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. Int J Pharm. 1991;70(3):235-240.
91. Campbell BJ. Biochemical and functional aspects of mucus and mucin-type glycoproteins. In: Mathiowitz E, Chickering DE, Lehr CM, editors. Bioadhesive drug delivery systems-fundamentals, novel approaches, and development. New York: Marcel Dekker, 1999.
92. Lehr CM. Lectin-mediated drug delivery: the second generation of bioadhesives. J Control Release. 2000;65(1-2):19-29.
93. Bies C, Lehr CM, Woodley JF. Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev. 2004;56(4):425-435.
94. Arbos P, Arangoa MA, Campanero MA, Irache JM. Quantification of the bioadhesive properties of protein-coated PVM/MA nanoparticles. Int J Pharm. 2002;242(1-2):129-136.
95. Lehr CM, Bouwstra JA, Kok W, Noach AB, de Boer AG, Junginger HE. Bioadhesion by means of specific binding of tomato lecitin. Pharm Res. 1992;9(4):547-553.
96. Irache JM, Durrer C, Duchene D, Ponchel G. Bioadhesion of lectin-latex conjugates to rat intestinal mucosa. Pharm Res. 1996;13(11):1716-1719.
97. Russell-Jones GJ, Veitch H, Arthur L. Lectin-mediated transport of nanoparticles across Caco-2 and OK cells. Int J Pharm. 1999;190(2):165-174.
98. Weissenbock A, Wirth M, Gabor F. WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. J Control Release. 2004;99(3):383-392.
99. Montisci MJ, Dembri A, Giovannuci G, Chacun H, Duchene D, Ponchel G. Gastrointestinal transit and mucoadhesion of colloidal suspensions of Lycopersicon esculentum L. and Lotus tetragonolobus lectin-PLA microsphere conjugates in rats. Pharm Res. 2001;18(6):829-837.
100. Naisbett B, Woodley J. The potential use of tomato lectin for oral drug delivery: 3. Bioadhesion in vivo. Int J Pharm. 1995;114(2):227-236.
101. Irache JM, Durrer C, Duchene D, Ponchel G. In vitro study of lectin-latex conjugates for specific bioadhesion. J Control Release. 1994;31(2):181-188.
102. Wirth M, Gerhardt K, Wurm C, Gabor F. Lectin-mediated drug delivery: influence of mucin on cytoadhesion of plant lectins in vitro. J Control Release. 2002;79(1-3):183-191.
103. Smart JD, Banchonglikitkul C, Gibbs RV, Donovan SJ, Cook DJ. Lectins in drug delivery to the oral cavity, in vitro toxicity studies. STP Pharma Sci. 2003;13(1):37-40.
104. Smart JD. Lectin-mediated drug delivery in the oral cavity. Adv Drug Deliv Rev. 2004;56(4):481-489.
105. Naisbett B, Woodley J. The potential use of tomato lectin for oral drug delivery: 4. Immunological consequences. Int J Pharm. 1995;120(2):247-254.
106. Gabor F, Bogner E, Weissenboeck A, Wirth M. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev. 2004;56(4):459-480.
107. Ritschel WA. Microemulsions for improved peptide absorption from the gastrointestinal tract. Method Find Exp Clin Pharmacol. 1991;13(3):205-220.
108. Constantinides PP, Scalart JP, Lancaster C, Marcello J, Marks G, Ellens H, et al. Formulation and intestinal absorption enhancement evaluation of water-in-oil microemulsions incorporating medium-chain glycerides. Pharm Res. 1994;11(10):1385-1390.
109. Nefzger M, Kreuter J, Voges R, Liehl E, Czok R. Distribution and elimination of polymethyl methacrylate nanoparticles after peroral administration to rats. J Pharm Sci. 1984;73(9):1309-1311.
110. LeFèvre ME, Boccio AM, Joel DD. Intestinal uptake of fluorescent microspheres in young and aged mice. Proc Soc Exp Biol Med. 1989;190(1):23-27.
111. Jani P, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol. 1989;41(12):809-812.
112. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol. 1990;42(12):821-826.
113. Jani PU, Florence AT, McCarthy DE. Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat. Int J Pharm. 1992;84(3):245-252.
114. Florence AT, Hillery AM, Hussain N, Jani PU. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J Drug Target. 1995;3(1):65-70.
115. Eyles J, Alpar O, Field WN, Lewis DA, Keswick M. The transfer of polystyrene microspheres from the gastrointestinal tract to the circulation after oral administration in the rat. J Pharm Pharmacol. 1995;47(7):561-565.
116. McMinn LH, Hodges GM, Carr KE. Gastrointestinal uptake and translocation of microparticles in the streptozotocin-diabetic rat. J Anat. 1996;189(Pt 3):553-559.
117. Le Ray AM, Vert M, Gautier JC, Benoit JP. Fate of [14 C] poly(D,L-lactide-co-glycolide) nanoparticles after intravenous and oral administration to mice. Int J Pharm. 1994;106(3):201-211.
118. Damge C, Aprahamian M, Marchais H, Benoit JP, Finget M. Intestinal absorption of PLAGA microspheres in the rat. J Anat. 1996;189(Pt 3):491-501.
119. Lavelle EC, Sharif S, Thomas NW, Holland J, Davis SS. The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv Drug Deliv Rev. 1995;18(1):5-22.
120. Thomas NW, Jenkins PG, Howard KA, Smith MW, Lavelle EC, Holland J, et al. Particle uptake and translocation across epithelial membranes. J Anat. 1996;189(Pt 3):487-490.
121. Florence AT. The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual. Pharm Res. 1997;14(3):259-266.
122. O'Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev. 1998;34(2-3):305-320.
123. Florence AT, Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev. 2001;50(1):S69-S89.
124. Cui Z, Mumper RJ. Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit Rev Ther Drug Carrier Syst. 2003;20(2-3):103-137.
125. Alpar HO, Eyles JE, Williamson ED. Oral and nasal immunization with microencapsulated clinically relevant proteins. STP Pharma Sci. 1998;8(1):31-39.
126. Hodges GM, Carr EA, Hazzard RA, O'Reilly C, Carr KE. A commentary on morphological and quantitative aspects of microparticle translocation across the gastrointestinal mucosa. J Drug Target. 1995;3(1):57-60.
127. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 1996;13(12):1838-1845.
128. Hillery AM, Jani PU, Florence AT. Comparative, quantitative study of lymphoid and non-lymphoid uptake of 60 nm polystyrene particles. J Drug Target. 1994;2(2):151-156.
129. Jenkins PG, Howard KA, Blackball NW, Thomas NW, Davis SS, O'Hagan DT. Microparticulate absorption from the rat intestine. J Control Release. 1994;29(3):339-350.
130. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release. 1990;11(1-3):205-214.
131. Ebel JP. A method for quantifying particle absorption from the small intestine of the mouse. Pharm Res. 1990;7(8):848-851.
132. Jepson MA, Simmons NL, O'Hagan DT, Hirst BH. Comparison of poly(D,L-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. J Drug Target. 1993;1(3):245-249.
133. Florence AT, Hillery AM, Hussain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release. 1995;36(1-2):39-46.
134. Hillery AM, Florence AT. The effect of adsorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60-nm polystyrene particles after oral administration in the rat. Int J Pharm. 1996;132(1-2):123-130.
135. Seifert J, Haraszti B, Sass W. The influence of age and particle number on absorption of polystyrene particles from rat gut. J Anat. 1996;189:483-486.
136. O'Hagan DT. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat. 1996;189(Pt 3):477-482.
137. Kreuter J. Peroral administration of nanoparticles. Adv Drug Deliv Rev. 1991;7(1):71-86.
138. Foster N, Ann Clark M, Jepson MA, Hirst BH. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. Vaccine. 1998;16(5):536-541.
139. Smith MW, Thomas NW, Jenkins PG, Miller NGA, Cremaschi D, Porta C. Selective transport of microparticles across Peyer's patch follicle-associated M cells from mice and rats. Exp Physiol. 1995;80(5):735-744.
140. Porta C, James PS, Phillips AD, Savidge TC, Smith MW, Cremaschi D. Confocal analysis of fluorescent bead uptake by mouse Peyer's patch follicle-associated M cells. Exp Physiol. 1992;77(6):929-932.
141. Pappo J, Ermak TH, Steger HJ. Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells. Immunology. 1991;73(3):277-280.
142. Easson JH, Haltner E, Lehr CM. Bacterial invasion factors and lectins as second-generation bioadhesives. In: Mathiowitz E, Chickering DE, Lehr CM, editors. Bioadhesive drug delivery systems-fundamentals, novel approaches, and development. New York: Marcel Dekker, 1999.
143. Pusztai A, Bardocz S, Ewen WBS. Plant lectins for oral drug delivery to different parts of the gastrointestinal tract. In: Mathiowitz E, Chickering DE, Lehr CM, editors. Bioadhesive drug delivery systems-fundamentals, novel approaches, and development. New York: Marcel Dekker, 1999.
144. Hussain N, Jani PU, Florence AT. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm Res. 1997;14(5):613-618.
145. Hussain N, Florence AT. Utilizing bacterial mechanisms of epithelial cell entry: invasin-induced oral uptake of latex nanoparticles. Pharm Res. 1998;15(1):153-156.
146. Haltner E, Easson JH, Lehr CM. Lectins and bacterial invasion factors for controlling endo- and transcytosis of bioadhesive drug carrier systems. Eur J Pharm Biopharm. 1997;44(1):3-13.
147. Arbos P, Campanero MA, Arangoa MA, Irache JM. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. J Control Release. 2004;96(1):55-65.
148. Russell-Jones GJ, Arthur L, Walker H. Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. Int J Pharm. 1999;179(2):247-255.
149. Russell-Jones GJ. The potential use of receptor-mediated endocytosis for oral drug delivery. Adv Drug Deliv Rev. 2001;46(1-3):59-73.
150. Carreno-Gomez B, Woodley JF, Florence AT. Studies on the uptake of tomato lectin nanoparticles in everted gut sacs. Int J Pharm. 1999;183(1):7-11.
151. Jones DH, Corns S, McDonald S, Clegg JCS, Farrar GH. Poly(D,L-lactide-co- glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine. 1997;15(8):814-817.
152. Challacombe SJ, Rahman D, Jeffery H, Davis SS, O'Hagan DT. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology. 1992;76(1):164-168.
153. O'Hagan DT, McGee JP, Holmgren J, Mowat AM, Donachie AM, Mills KHG, et al. Biodegradable microparticles for oral immunization. Vaccine. 1993;11(2):149-154.
154. O'Hagan DT, Rahman D, Jeffery H, Sharif S, Challacombe SJ. Controlled release microparticles for oral immunization. Int J Pharm. 1994;108(2):133-139.
155. Challacombe SJ, Rahman D, O'Hagan DT. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine. 1997;15(2):169-175.
156. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AM. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in pory(lactide-co-glycolide) microparticles. Immunology. 1994;81(4):661-667.
157. Jung T, Kamm W, Breitenbach A, Hungerer KD, Hundt E, Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft- poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res. 2001;18(3):352-360.
158. O'Hagan DT, McGee JP, Lindblad M, Holmgren J. Cholera toxin B subunit (CTB) entrapped in microparticles shows comparable immunogenicity to CTB mixed with whole cholera toxin following oral immunization. Int J Pharm. 1995;119(2):251-255.
159. Conway M, Eyles J, Alpar HO. Systemic and local immune responses following oral and nasal delivery of microspheres of different sizes. J Pharm Pharmacol. 1997;49(S4):30.
160. Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres. Vaccine. 2002;20(17-18):2181-2190.
161. Jones DH, McBride BW, Thornton C, O'Hagan DT, Robinson A, Farrar GH. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection. Infect Immun. 1996;64(2):489-494.
162. Murillo M, Grillo MJ, Rene J, Marin CM, Barberan M, Goni MM, et al. A Brucella ovis antigenic complex bearing poly-[ε]-caprolactone microparticles confer protection against experimental brucellosis in mice. Vaccine. 2001;19(30):4099-4106.
163. Chen SC, Jones DH, Fynan EF, Farrar GH, Clegg JC, Greenberg HB, et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol. 1998;72(7):5757-5761.
164. Mesiha MS, Sidhom MB, Fasipe B. Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles. Int J Pharm. 2005;288(2):289-293.
165. Ma Z, Lim TM, Lim LY. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int J Pharm. 2005;293(1-2):271-280.
166. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2001;299(2):775-781.